The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Gastrointestinal Stromal Tumor (GIST): Diagnosis and Targeted Treatment

KIT and PDGFRA-driven mesenchymal sarcoma of the digestive tract

Written by: Saygı Hospital Health Guide Editorial Board
Published:

This content is for general information; please consult your physician for diagnosis and treatment.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Gastrointestinal Stromal Tumor (GIST): Diagnosis and Targeted Treatment?

GIST originates predominantly in the stomach (60 percent) and small intestine (30 percent), with rare colorectal, esophageal and extra-intestinal sites.

Most tumors carry mutations in KIT (about 75 percent), PDGFRA (10 percent) or are SDH-deficient (wild-type pediatric and young adult subset).

Diagnosis is based on histology with spindle or epithelioid cells, CD117 (KIT) and DOG1 immunostaining and confirmatory molecular testing.

Risk stratification uses tumor size, mitotic rate, anatomical site and rupture status to predict relapse.

Imaging with contrast-enhanced CT and biopsy with endoscopic ultrasound guide preoperative planning.

Symptoms

Vague abdominal discomfort, early satiety and bloating, particularly with gastric tumors.
Gastrointestinal bleeding presenting as melena, hematemesis, anemia or fatigue.
Palpable abdominal mass in larger tumors with possible compression of adjacent organs.
Bowel obstruction symptoms with small intestinal lesions including pain and vomiting.
Many small tumors are incidental findings on endoscopy or imaging performed for unrelated reasons.

Risk Factors

Sporadic somatic KIT or PDGFRA mutations are the dominant driver.
Familial GIST syndromes with germline KIT mutations are rare.
Carney triad and Carney-Stratakis syndrome predispose to SDH-deficient GIST in younger patients.
Neurofibromatosis type 1 increases risk of small intestinal GIST.
Age over 40, prior gastrointestinal stromal pathology and certain ethnic backgrounds influence incidence.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Significant gastrointestinal bleeding, severe abdominal pain or rapidly enlarging mass requires urgent surgical evaluation.
  • New unexplained iron deficiency anemia, melena or weight loss should prompt endoscopic and imaging workup.
  • Postoperative patients with new symptoms or rising imaging findings need restaging and oncology review.
  • Patients on tyrosine kinase inhibitors with severe edema, rash, hepatotoxicity or cardiac symptoms need prompt assessment.
  • Long-term surveillance is essential because of late recurrences and potential mutation evolution.

Treatment Methods

01
Complete surgical resection with negative margins is the cornerstone for localized disease, avoiding tumor rupture.
02
Adjuvant imatinib is recommended for high-risk resected GIST, typically for at least 3 years and longer in selected patients.
03
Imatinib is the standard first-line therapy for advanced or metastatic disease with KIT-sensitive mutations.
04
Sunitinib is approved for imatinib-resistant or intolerant disease, with regorafenib, ripretinib and avapritinib for further lines.
05
Multidisciplinary care, mutation-guided dose adjustments, surveillance imaging and management of toxicities are essential, with selected metastasectomy and clinical trials in resistant disease.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.